Posted by Michael Wonder on 27 Jul 2020
Imfinzi recommended for approval in the EU by CHMP for extensive-stage small cell lung cancer
27 July 2020 - Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit and improved response rate in combination with a choice of chemotherapies.
AstraZeneca’s Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for the first-line treatment of adults with extensive-stage small cell lung cancer in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.
The CHMP of the European Medicines Agency based its positive opinion on results from the Phase III CASPIAN trial for Imfinzi plus chemotherapy, which have also been published in The Lancet.
